Nonrelapse mortality by total nucleated cell dose. (A) The cumulative incidence of nonrelapse mortality by precryopreserved TNC in recipients of 1-allele mismatched transplants: 45% (95% CI 29-62), 24% (95% 13-38), and 21% (14-28) for units with TNC <3 × 10⁷/kg, 3-5 × 10⁷/kg, and >5 × 10⁷/kg, respectively. (B) The cumulative incidence of nonrelapse mortality by precryopreserved TNC in recipients of 2-allele mismatched transplants: 40% (95% CI 27-53), 25% (95% 17-34), and 23% (18-28) for units with TNC <3 × 10⁷/kg, 3-5 × 10⁷/kg, and >5 × 10⁷/kg, respectively. (C) The cumulative incidence of nonrelapse mortality by precryopreserved TNC in recipients of 3-allele mismatched transplants: 52% (95% CI 39-64), 35% (95% 27-42), and 29% (23-35) for units with TNC <3 × 10⁷/kg, 3-5 × 10⁷/kg, and >5 × 10⁷/kg, respectively. (D) The cumulative incidence of nonrelapse mortality by precryopreserved TNC in recipients of 4-allele mismatched transplants: 43% (95% CI 28-58), 39% (95% 30-49), and 29% (21-39) for units with TNC <3 × 10⁷/kg, 3-5 × 10⁷/kg and >5 × 10⁷/kg, respectively.